Novartis
955.00
+11.40(+1.21%)
Market Cap₹3,309.72 Cr
PE Ratio23.96
IndustryHealthcare
Company Performance:
1D+1.21%
1M+13.74%
6M+3.71%
1Y+20.78%
5Y+58.44%
View Company Insightsright
More news about Novartis
30Dec 25
Novartis India Board Meeting on January 28, 2026 for Q3FY26 Financial Results
Novartis India Limited has officially announced its Board of Directors meeting scheduled for January 28, 2026, to consider and approve Q3FY26 unaudited financial results. The company has implemented a trading window closure from January 1, 2026, for designated persons in compliance with SEBI regulations, with reopening 48 hours after results declaration.
 no imag found
28Oct 25
Novartis India Reports Robust Q2 Performance with 33% EBITDA Growth
Novartis India Limited announced its Q2 FY2026 financial results, showing significant improvements. Revenue increased by 4% to ₹903.00 crore, EBITDA grew by 33% to ₹239.00 crore, and net profit rose by 19% to ₹242.00 crore. The company's EBITDA margin expanded by 582 basis points to 26.44%. The Board of Directors met on October 28, 2025, to approve these results.
 no imag found
29Jul 25
Novartis India Reports Q1 Results, Appoints Cost Auditors
Novartis India Limited reported Q1 revenue of ₹875.50 crore, down 5.1% year-over-year but up 4.4% quarter-over-quarter. Profit increased 7.3% year-over-year to ₹276.20 crore. The company appointed M/s. D.C. Dave & Co. as Cost Auditors for the upcoming fiscal year, with a remuneration of ₹1.50 lakh plus taxes, subject to shareholder approval via postal ballot.
 no imag found
09May 25
Novartis India Reports Robust Q4 Results, Declares ₹25 Dividend
Novartis India Limited has released its Q4 financial results, showing significant improvements across key metrics. Revenue increased by 3.36% to ₹839.00 crore. EBITDA more than doubled to ₹239.00 crore, with the EBITDA margin expanding to 28.49%. Net profit surged by 99.59% to ₹293.00 crore. The company's board has recommended a dividend of ₹25.00 per equity share.
 no imag found
Novartis
955.00
+11.40
(+1.21%)
1 Year Returns:+20.78%
Industry Peers
Sun Pharmaceutical
1,825.90
(+0.72%)
Divis Laboratories
6,352.50
(-0.31%)
Torrent Pharmaceuticals
4,431.20
(+0.08%)
Dr Reddys Laboratories
1,325.50
(+0.83%)
Cipla
1,329.50
(-0.30%)
Lupin
2,344.60
(+0.31%)
Zydus Life Science
921.75
(-0.15%)
Mankind Pharma
2,243.80
(+0.27%)
Aurobindo Pharma
1,304.80
(+1.47%)
Alkem Laboratories
5,544.50
(-1.28%)